Investigational Drug Information for Intepirdine
✉ Email this page to a colleague
What is the drug development status for Intepirdine?
Intepirdine is an investigational drug.
There have been 5 clinical trials for Intepirdine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 26th 2016.
The most common disease conditions in clinical trials are Lewy Body Disease, Dementia, and Alzheimer Disease. The leading clinical trial sponsors are Axovant Sciences Ltd. and [disabled in preview].
There are twelve US patents protecting this investigational drug and one hundred and eighty international patents.
Summary for Intepirdine
| US Patents | 12 |
| International Patents | 180 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 44 |
| Japanese Patent Applications | 20 |
| Clinical Trial Progress | Phase 3 (2016-04-26) |
| Vendors | 51 |
Recent Clinical Trials for Intepirdine
| Title | Sponsor | Phase |
|---|---|---|
| Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia | Axovant Sciences Ltd. | Phase 2 |
| Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension | Axovant Sciences Ltd. | Phase 2/Phase 3 |
| 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension | Axovant Sciences Ltd. | Phase 3 |
Clinical Trial Summary for Intepirdine
Top disease conditions for Intepirdine
Top clinical trial sponsors for Intepirdine
US Patents for Intepirdine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Intepirdine | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Intepirdine | ⤷ Sign Up | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, UT) | ⤷ Sign Up |
| Intepirdine | ⤷ Sign Up | Methods of treating dementia and pharmaceutical compositions thereof | H. LUNDBECK A/S (Valby, DK) | ⤷ Sign Up |
| Intepirdine | ⤷ Sign Up | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity | H. Lundbeck A/S (Valby, DK) | ⤷ Sign Up |
| Intepirdine | ⤷ Sign Up | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. Lundbeck A/S (Valby, DK) | ⤷ Sign Up |
| Intepirdine | ⤷ Sign Up | Piperazine derivative having affinity for the histamine H3 receptor | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Intepirdine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Intepirdine | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Intepirdine | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Intepirdine | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Intepirdine | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Intepirdine | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Intepirdine | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
